Navigation Links
New approach for tuberculosis drugs
Date:7/2/2014

Consumption was one of the worst known diseases of the 18th century. Thanks to medical advances, the number of deaths from this lung disease which is today known as tuberculosis has declined significantly. Efforts to eradicate the disease in the 1950s and 1960s resulted in a wide range of new drugs entering the market.

And yet 1.4 million people still continue to die each year from tuberculosis. Multidrug-resistant strains of the disease-causing pathogen are especially dangerous because they can no longer be treated with today's drugs (see box). "In the past 50 years, only one new tuberculosis drug has come on to the market, and that was in 2012," says Karl-Heinz Altmann, Professor of Pharmaceutical Biology at ETH Zurich. New active substances that are able to kill multidrug-resistant strains of the disease are therefore urgently needed. Altmann and his team have now laid the foundation for new tuberculosis drugs, and they were inspired by a bacteria-derived antibiotic called pyridomycin.

New design for greater efficacy

Pyridomycin inhibits the growth of the tuberculosis pathogen Mycobacterium tuberculosis, but it is degraded relatively quickly and is therefore ineffective. However, by using the structure of pyridomycin, Altmann and his research group have designed a molecule that has several advantages over the natural active substance. The new molecule is more stable and is easier to produce synthetically; it can also serve as a lead structure for the synthesis and biological testing of further modified versions of the active substance. Drugs could eventually be developed that work efficiently and are well tolerated. They could also be be adapted such as to overcome new drug-resistant strains of the tuberculosis pathogen. The researchers have applied for a patent for the new active substance's basic structure and the method of production.

The researchers found inspiration from a long forgotten substance. In 1953, Japanese scientists discovered that pyridomycin inhibits the growth of the tuberculosis pathogen Mycobacterium tuberculosis. But the compound was not investigated further for decades thereafter. "Everyone behaved as though the tuberculosis problem was solved," says Altmann. While researching the literature, he came across the pyridomycin and worked together with a research team led by Stewart Cole, a professor of microbial pathogenesis at EPFL, to decode how it works. It paralyses an important component of cellular metabolism, which is essential for building the cell wall of the tuberculosis pathogen. Although an available drug called isoniazid targets the same key protein , it must first be converted inside the tuberculosis bacteria into the actual inhibitor. Pyridomycin, in contrast, binds directly to the target protein and therefore circumvents pre-existing resistance mechanisms that prevent isoniazid from becoming activated. The new approach of the active substance enables a wide variety of structures for new drugs against tuberculosis.


'/>"/>

Contact: News & Media Relations
mediarelations@hk.ethz.ch
41-446-324-141
ETH Zurich
Source:Eurekalert

Related biology news :

1. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
2. A project to research biological and chemical aspects of microalgae to fuel approach
3. UofL research holds promise of therapeutic approach for gum disease
4. Approach to diabetes self-management too narrow, study suggests
5. Manatee hearing good enough to sense approaching motorboats
6. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
7. New approach to spell checking gene sequences
8. Powerful new approach to attack flu virus
9. Potential new approach to regenerating skeletal muscle tissue
10. Bugs have key role in farming approach to storing CO2 emissions
11. Computing advances vital to sustainability efforts; new report recommends problem-focused, iterative approach to research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
Breaking Biology News(10 mins):
(Date:6/22/2016)... 22, 2016 Cell Applications, Inc. and ... to produce up to one billion human induced ... one week. These high-quality, consistent stem cells enable ... and spend more time doing meaningful, relevant research. ... high-volume manufacturing process that produces affordable, reliable HiPSC ...
(Date:6/22/2016)... ANGELES , June 22, 2016   StockNewsNow.com ... SNNLive Video Interview with Dr. Nader Pourhassan , ... biotechnology company focused on the clinical development and potential ... prevention of HIV infection, according to the company,s website ... recorded on Tuesday, June 7 th , 2016, at ...
(Date:6/22/2016)... ... June 21, 2016 , ... New light-based technologies that facilitate ... tissue — promise to enable both compact, wearable devices for point-of-care diagnostics as well ... the skin. , Recent work and visionary future directions are detailed in a new ...
(Date:6/22/2016)... and ALBANY, N.Y. ... Corporation (Teewinot) and Albany Molecular Research, Inc. (NASDAQ: ... has licensed Teewinot,s technology to produce and sell ... standard. The CBCA analytical standard is manufactured using ... the expression of cannabinoid biosynthetic genes in microorganisms ...
Breaking Biology Technology: